GLP-1 விளக்கம்: இந்திய நோயாளிகளுக்கான முழுமையான வழிகாட்டி
Semaglutide, tirzepatide கேள்விப்பட்டு உங்களுக்கு பொருத்தமா என்று யோசித்திருந்தால், தனியாக இல்லை. GLP-1 ரிசெப்டர் அகோனிஸ்ட்கள் worldwide type 2 diabetes, obesity approach மாற்றியுள்ளன—இந்தியா exception அல்ல. GLP-1 என்ன, body-இல் எவ்வாறு work, RSSDI/ICMR/CDSCO framework-இல் access, cost, safety—இந்திய நோயாளிகளுக்கு relevant. Newly diagnosed type 2 diabetes, normal-range BMI central obesity, குடும்ப உறுப்பினர் option explore—drug class literacy (brand marketing அல்ல) productive medical conversation foundation. South Asian unique metabolic pattern, lower insurance, growing generic access—2026-இல் drug-class literacy valuable.
Short answer
GLP-1 ரிசெப்டர் அகோனிஸ்ட்கள் (GLP-1 RA) gut hormone-ஐ mimic செய்யும் injectable/oral மருந்து வகை; பசி குறைப்பு, வயிற்று காலியாகும் வேகம் மெதுவாக்குதல், இரத்த சர்க்கரை கட்டுப்பாடு. இந்தியாவில் type 2 diabetes; தேர்ந்தெடுக்கப்பட்ட obesity-க்கு BMI ≥27.5 kg/m² அல்லது comorbidity-உடன் ≥25. Doctor prescription, CDSCO-approved sourcing, gradual dose titration தேவை. RSSDI, ICMR Indian clinician use shape. Kesho கல்வி மட்டும்—prescribe/sell இல்லை. Purchase-க்கு முன் product approval verify.
Key takeaways
- •GLP-1 ரிசெப்டர் அகோனிஸ்ட்கள் ஒரு drug class—single product அல்ல—இயற்கை gut hormone mimic செய்து இரத்த சர்க்கரை மேம்படுத்தி பசியைக் குறைக்கின்றன.
- •இந்தியாவில் RSSDI, ICMR South Asian lower body weight-இல் metabolic disease—earlier BMI threshold (≥27.5 அல்லது comorbidity-உடன் ≥25) support.
- •எல்லா GLP-1 RA Schedule H prescription medicine; CDSCO unapproved import, social-media seller-க்கு எதிராக எச்சரிக்கை.
- •Dose titration-உடன் weeks-இல் நன்மை build; first month nausea common—smaller meal, gradual dose increase-இல் usually improve.
- •Indian dietary pattern, physical activity, regular monitoring-உடன் medication best—standalone shortcut அல்ல.
GLP-1 என்றால் என்ன?
GLP-1 (glucagon-like peptide-1) உணவுக்குப் பிறகு gut வெளியிடும் hormone. இரத்த சர்க்கரை rise-ஆன pancreas insulin release signal, glucagon (blood sugar raise hormone) reduce, brain-க்கு full signal. GLP-1 ரிசெப்டர் அகோனிஸ்ட்கள் (GLP-1 RA) இந்த hormone mimic. Drug class—not single brand—semaglutide, liraglutide, dulaglutide, dual GIP/GLP-1 tirzepatide. India Schedule H: registered medical practitioner valid prescription only dispense. CDSCO approval, labelling, pharmacovigilance regulate. Drug class understand brand marketing without informed doctor conversation. Many patient metformin/lifestyle alone HbA1c control insufficient, excess weight insulin resistance/fatty liver modest BMI-இல் first encounter GLP-1 RA. RSSDI type 2 diabetes pathway first-line insufficient glycaemic target GLP-1 RA important option.
GLP-1 receptor agonist
Pancreas, brain, gut GLP-1 receptor activate—blood sugar control improve, appetite reduce medication.
GLP-1 ரிசெப்டர் அகோனிஸ்ட்கள் body-இல் எவ்வாறு work?
GLP-1 RA எடுக்கும்போது sequence-இல் several happen. First pancreas insulin release stimulate—blood glucose elevated-ஆன only, sulfonylurea போல older diabetes drug compare low blood sugar risk reduce. Second gastric emptying slow—food stomach longer, smaller portion satisfied. Third brain appetite centre act—craving, emotional eating trigger reduce. STEP (semaglutide), SURMOUNT (tirzepatide) trial lifestyle change combine meaningful weight loss, HbA1c improvement. Dose titrate upward weeks-இல் gradually effect build—first 2–3 month patience matter. First week nausea common, body adapt/dose slowly increase (dose titration) improve. Large traditional Indian meal patient delayed stomach emptying unfamiliar; smaller frequent portion single heavy dinner better.
India GLP-1 approved use எவை?
India GLP-1 RA primarily adult type 2 diabetes diet, exercise, metformin first-line insufficient. RSSDI drug class position glycaemic control need—cardiovascular risk, obesity, chronic kidney disease, other medicine hypoglycaemia concern favour. Obesity management ICMR national guideline, RSSDI consensus Western guideline lower BMI threshold—South Asian lower body weight metabolic complication. BMI 27.5 kg/m²+, or 25 kg/m²+ prediabetes, fatty liver, hypertension, dyslipidaemia comorbidity pharmacotherapy consider appropriate patient. Final eligibility treating physician full medical history, current medication, investigation review. Cardiovascular outcome trial some molecule beyond glucose control high-risk established heart disease benefit. Type 1 diabetes not indicated; diabetic ketoacidosis insulin substitute not.
Kesho GLP-1 medication prescribe/sell இல்லை. இந்த article கல்வி. Personalised medical advice qualified endocrinologist, internal medicine specialist, cardiologist consult.
Indian BMI threshold Western guideline-இலிருந்து ஏன் differ?
Indian, South Asian population "thin-fat" phenotype frequent: scale normal/modest BMI, higher visceral (belly) fat, lower muscle. Insulin resistance, fatty liver, early type 2 diabetes link. Chennai BMI 26 person Europe same BMI compare more metabolic risk. RSSDI, ICMR guideline earlier intervention reflect. Conventional chart "normal" weight central obesity, elevated HbA1c, ultrasound fatty liver doctor GLP-1 therapy broader metabolic plan discuss. Waist circumference—South Asia men often 90 cm+, women 80 cm+—BMI alongside clinician practical measure. Body composition scale number alone—Western online calculator self-assessment Indian patient misleading.
India GLP-1 medication legally access எவ்வாறு?
India GLP-1 RA innovator product, increasingly CDSCO-approved generic semaglutide patent development follow. Monthly out-of-pocket ~₹8,000–₹25,000 molecule, dose, city—most family significant expense. Licenced pharmacy valid prescription purchase. CDSCO unapproved import, compounded formulation, prescription without social-media steep discount seller advisory. CDSCO approval, proper labelling, batch, expiry verify. Cold-chain injectable pen first use before 2°C–8°C refrigerate; after first use most pen 30°C below several week manufacturer CDSCO-approved guideline. Metro pharmacist cold-chain familiar; tier-2/3 city dispensing counter storage confirm.
GLP-1 RA common diabetes medicine compare?
- Feature: Primary action — GLP-1 RA: GLP-1 hormone mimic; appetite reduce — Metformin: Liver glucose output reduce — Sulfonylureas: Insulin release stimulate
- Feature: Weight effect — GLP-1 RA: Usually loss promote — Metformin: Neutral/slight loss — Sulfonylureas: Often gain promote
- Feature: Hypoglycaemia risk alone — GLP-1 RA: Low — Metformin: Very low — Sulfonylureas: Moderate to high
- Feature: Route India — GLP-1 RA: Injection (weekly/daily) or oral tablet — Metformin: Oral tablet — Sulfonylureas: Oral tablet
- Feature: Typical RSSDI position — GLP-1 RA: Metformin after target unmet — Metformin: Most T2D first-line — Sulfonylureas: Hypoglycaemia/weight declining use
Medically reviewed
Dr. Ananya Mehta, MD, DM Endocrinology
Consultant Endocrinologist, India
This article has been reviewed by our medical advisory team, including endocrinologists, internal medicine specialists, and cardiologists, and is based on current scientific evidence and Indian clinical guidelines. Last reviewed: June 2026.
Last medically reviewed: Jun 26, 2026